Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Socialization of the Key Elements of Practice Redesign in Community Pharmacies: The 2025-2026 AACP Professional Affairs Standing Committee Report.

American journal of pharmaceutical education·2026
Same author

Community pharmacy practice transformation: Evaluating sustainability of patient care services.

Journal of the American Pharmacists Association : JAPhA·2026
Same author

A Pharmacist Consultant Service for Deprescribing Opioids and Benzodiazepines in Older Adults: A Cluster Randomized Trial.

JAMA network open·2026
Same author

Examining rural community pharmacists' knowledge and practices in opioid overdose prevention and treatment services in the Southeastern United States.

Harm reduction journal·2025
Same author

Implementing payer partnerships for patient care programs within clinically integrated networks of community pharmacies: A qualitative study.

Journal of the American Pharmacists Association : JAPhA·2025
Same author

It Is a Good Idea, but Are They Willing? Assessing Pharmacist Willingness to Deliver Colorectal Cancer Screening.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2025

Related Experiment Video

Updated: May 10, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Evaluating the economic impact of a targeted medication intervention program.

Sarah A Rhodes1, Abigale E Reynolds, Macary W Marciniak

  • 1Physicians Pharmacy Alliance, Cary, NC, USA.

Journal of Pharmacy Practice
|June 28, 2013
PubMed
Summary

A community pharmacy

Keywords:
community pharmacymedication therapy managementpharmacistsreturn on investmenttargeted medication intervention

Related Experiment Videos

Last Updated: May 10, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Area of Science:

  • Pharmacy Practice
  • Health Economics
  • Medication Management

Background:

  • Community pharmacies offer targeted medication intervention programs.
  • Evaluating the financial viability of these programs is crucial for sustainability.

Purpose of the Study:

  • To determine the return on investment (ROI) for a community pharmacy's targeted medication intervention program.
  • To identify the time efficiency required for the program to achieve financial break-even.

Main Methods:

  • Retrospective analysis of interventions and a cross-sectional survey of pharmacists.
  • Data collected from a regional community pharmacy chain in North Carolina.
  • Calculated costs, revenue, and ROI over a 6-month period.

Main Results:

  • The program yielded a negative 3% ROI over six months.
  • The average intervention time was 22.63 minutes.
  • Total costs were $15,760.86 and total revenue was $15,216.00.

Conclusions:

  • The targeted medication intervention program resulted in a financial loss for the pharmacy chain.
  • To break even, the average intervention time must be 21.85 minutes or less under the current reimbursement structure.